Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study

Autor:	José L. Ruiz-Cerdá, José M Cózar-Olmo, Rafael Medina-López, José Manasanch, Federico Rodríguez-Rubio, Víctor Baena-González, Miguel Unda-Urzaiz, Joaquín Carballido-Rodríguez, Francisco J Brenes-Bermúdez, Darío García-Rojo, Antonio Alcaraz
Přispěvatelé:	[Alcaraz,A] Urology Department, Hosp. Clínic Univ., IDIBAPS, Barcelona, Spain . [Carballido-Rodríguez,J] Urology Department, Hosp. Univ. Puerta de Hierro, Majadahonda, Madrid, Spain. [Unda-Urzaiz,M] Urology Department, Hosp. Univ. Basurto, Bilbao, Spain. [Medina-López,R] Urology Department, Hosp. Univ. Virgen del Rocío, Sevilla, Spain. [Ruiz-Cerdá,JL] Urology Department, Hosp. Univ. La Fe, Valencia, Spain. [Rodríguez-Rubio,F] Department, Hosp. Univ. Puerto Real, Cádiz, Spain. [García-Rojo,D] Urology Department, Hosp. Univ. Parc Taulí Sabadell, Sabadell, Barcelona, Spain. [Brenes-Bermúdez,FJ] Llefià Primary Care Center, Badalona, Barcelona, Spain. [Cózar-Olmo,JM] Urology Department, Complejo Hospitalario Universitario de Granada, Granada, Spain. [Baena-González,V]Urology Department, Hosp. Univ. Carlos Haya, Málaga, Spain.[Manasanch,J] Pierre Fabre Ibérica S.A., Barcelona, Spain., This study was funded by Pierre Fabre Ibérica
Rok vydání:	2015
Předmět:	Male Fitoterapia Inhibidores de 5-alfa-reductasa Urología medicine.medical_treatment Calidad de vida Health Care::Health Services Administration::Quality of Health Care::Outcome and Process Assessment (Health Care)::Outcome Assessment (Health Care)::Watchful Waiting [Medical Subject Headings] 030232 urology & nephrology Espera vigilante Prostatic Hyperplasia Instituciones de atención ambulatoria urologic and male genital diseases Severity of Illness Index Diseases::Male Urogenital Diseases::Genital Diseases Male::Prostatic Diseases::Prostatic Hyperplasia [Medical Subject Headings] Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] chemistry.chemical_compound 0302 clinical medicine Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Adrenergic Agents::Adrenergic Antagonists::Adrenergic alpha-Antagonists [Medical Subject Headings] 5-alpha Reductase Inhibitors Quality of life Serenoa Estudios prospectivos Prostatism Longitudinal Studies Prospective Studies Prospective cohort study Extractos vegetales Sulfonamides Urology - Original Paper IPSS LUTS Finasteride Antagonistas adrenérgicos alfa Middle Aged Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Complementary Therapies::Phytotherapy [Medical Subject Headings] Oxidorreductasas Organisms::Eukaryota::Plants::Viridiplantae::Streptophyta::Embryophyta::Angiosperms::Arecaceae::Serenoa [Medical Subject Headings] Nephrology 030220 oncology & carcinogenesis BPH Drug Therapy Combination medicine.drug Change over time Tamsulosin medicine.medical_specialty Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings] Urology MEDLINE Check Tags::Male [Medical Subject Headings] Hiperplasia prostática Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Urological Manifestations::Lower Urinary Tract Symptoms [Medical Subject Headings] 03 medical and health sciences Quality of life (healthcare) Text mining Lower Urinary Tract Symptoms Lower urinary tract symptoms Disciplines and Occupations::Social Sciences::Quality of Life [Medical Subject Headings] Internal medicine Real-life practice medicine In real life Humans In patient Síntomas del sistema urinario inferior Chemicals and Drugs::Complex Mixtures::Biological Agents::Plant Preparations::Plant Extracts [Medical Subject Headings] Watchful Waiting BII Adrenergic alpha-Antagonists Aged Gynecology business.industry Plant Extracts Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::5-alpha Reductase Inhibitors [Medical Subject Headings] Dutasteride medicine.disease Health Care::Health Care Facilities Manpower and Services::Health Facilities::Ambulatory Care Facilities [Medical Subject Headings] Disciplines and Occupations::Health Occupations::Medicine::Specialties Surgical::Urology [Medical Subject Headings] chemistry Quality of Life sense organs business Watchful waiting Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Oxidoreductases [Medical Subject Headings] Phytotherapy
Zdroj:	International Urology and Nephrology
ISSN:	1573-2584
Popis:	Journal Article; PURPOSE To evaluate change in quality of life (QoL) and symptoms in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in conditions of current clinical practice. METHODS Prospective, longitudinal, multicenter open-label study was carried out in urology outpatient clinics. Patients were ≥40 years of age with an International Prostate Symptom Score (IPSS) score ≥8. QoL and symptoms were measured at baseline and 6 months using the Benign Prostatic Hyperplasia Impact Index (BII) and the IPSS. RESULTS 1713 patients were included for analysis. Mean (SD) IPSS and BII scores at baseline were 16.8 (5.4) and 6.8 (2.6), respectively. 8.9 % (n = 153) of study participants did not receive treatment (watchful waiting, WW), 70.3 % (n = 1204) were prescribed monotherapy (alpha-adrenergic blockers [AB]; phytotherapy [PT, of which 95.2 % was the hexanic extract of Serenoa repens, HESr]; or 5-alpha-reductase inhibitors [5ARI]), and 20.8 % (n = 356) received combined treatment (AB + 5ARI; AB + HESr; others). At 6 months, improvements in QoL were similar across the different medical treatment (MT) groups, both for monotherapy (AB: mean improvement [SD] of 2.4 points [2.4]; PT: 1.9 [2.4]; 5ARI: 2.5 [2.3]) and combined therapy (AB + 5ARI: 3.1 [2.9]; AB + PT: 3.1 [2.5]). There were no clinically significant differences between MT groups and all showed significant improvement over WW (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bea758d8d7122b25856adb0f5a0d6ee5 https://pubmed.ncbi.nlm.nih.gov/28817870 Zobrazit plný text záznamu Full text from SpringerLink